Picture this: You’re at the top of One World Trade Center in 2015 when suddenly people start craning their necks and pulling out phones. Arnold Schwarzenegger just walked in. But here’s the thing—not everyone saw him at the same time. The person who left five seconds earlier? They had no idea.
Wall Street works exactly the same way.
Information doesn’t hit everyone simultaneously. Corporate insiders move first, then early birds (the analysts and industry watchers), then the early crowd, then the masses, and finally the bag-holders who show up when it’s already too late. This staggered flow of information is why momentum exists. Buying pressure builds as word spreads, creating what we call “breakout stocks”—companies that have caught early attention and are primed to surge as the crowd catches on.
Think Apple in 2015-2017. While everyone was panicking about iPhone sales, insiders and early buyers were quietly accumulating. By the time the masses realized Apple’s services business was a goldmine, early investors had already locked in 300% returns.
Today, two stocks are showing similar patterns.
The Biotech Moonshot: Larimar Therapeutics (LRMR)
Larimar is working on a drug for Friedreich’s ataxia, a rare neurodegenerative disease that hits kids between ages 5 and 15. Currently, there’s only one approved therapy on the market—Biogen’s Skyclarys—which costs $370,000 per year and generates over $500 million annually. The catch? It’s not even approved for children under 16.
Larimar’s drug targets the root cause more directly and early data suggests it’s actually more effective. If approved, we’re talking about a potential billion-dollar blockbuster.
Here’s where it gets interesting: Larimar just achieved Breakthrough Therapy designation and completed a capital raise. The company’s largest financial backers collectively bought almost $26 million of stock in the past week. Translation: the smart money is betting big. The firm is now on track to report clinical trial results in June 2026 with an expedited approval process following. That’s a clear catalyst timeline with adequate cash runway.
Yes, there’s risk—this is a single-drug biotech, and clinical trials can fail. But the risk-reward setup is compelling. Shares currently trade around $5; fair value is closer to $15 if data comes through positive.
The AI-Proof Play: Gray Media (GTN)
Here’s a contrarian take: streaming is about to get disrupted by AI-generated content. Netflix knows this. That’s why they’re aggressively pursuing sports deals and integrating generative AI into their own content. They’re also trying to acquire distribution networks because no matter how good AI-generated movies become, they need a visible platform to reach audiences.
Gray Media operates 180 TV stations across 113 markets—one of the few genuinely AI-resistant corners of media. Early investors are already noticing; shares are up 25% in the past month. As more investors realize that distribution is the real moat in an AI-saturated content world, Gray Media could see significant upside.
The Real Lesson
The takeaway isn’t just these two tickers. It’s recognizing that information spreads slowly, then fast. Those who spot the trend early—before the crowd arrives—are the ones who profit. These two stocks show the hallmarks of early-stage breakouts: clear catalysts, smart money already positioned, and catalysts that could trigger the next wave of buying.
The question is: will you be in the room when everyone else starts craning their necks?